Science Current Events | Science News | Brightsurf.com
 

Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels

May 11, 2012

Results from a randomized trial in head and neck cancer

Barcelona, Spain: Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumour and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can be overcome by the use of a treatment known as ARCON therapy, in which accelerated radiotherapy is combined with carbogen (a mixture of carbon dioxide and oxygen) and the water-soluble vitamin nicotinamide [1].

Hans Kaanders, a professor of translational radiation oncology at Radboud University Nijmegen Medical Centre, Nijmegen, will tell the 31st conference of the European Society for Radiotherapy and Oncology [2] today (Friday) that the ARCON regime is the first to show a positive effect in patients with low Hb levels.

The researchers recruited 345 patients with squamous cell laryngeal cancer to a randomised trial: 174 received only accelerated radiotherapy (where two fractions per day are administered during the last week of radiotherapy in order to reduce the overall length of treatment), and 171 ARCON. Patients receiving ARCON inhaled carbogen during radiotherapy and took nicotinamide tablets prior to treatment. Pre-treatment Hb levels in the experimental group were measured and subsequently compared with the treatment outcomes in the accelerated radiotherapy alone arm.

They found that patients treated with accelerated radiotherapy alone who had normal Hb levels before treatment had significantly better control of the cancer at its primary site (76% as opposed to 56%), disease-free survival (72% and 48% respectively), and metastasis-free survival (90% and 70%) than those with low Hb levels.

"However, when we looked at the ARCON group, in cases where the patients had low Hb levels before treatment, we found that ARCON improved control of the cancer at its primary site, and improved disease-free and metastasis-free survival, so that the differences between them and patients with normal Hb levels were no longer significant," says Professor Kaanders' colleague Dr. Geert Janssens. The difference in local control between this low Hb group and the normal Hb accelerated radiotherapy (AR) alone group was only 1% (81% in the ARCON group versus 82% in the AR-only group); for disease-free survival, the difference was 77% (ARCON) as opposed to 70% (AR); and for metastasis-free survival 93% (ARCON) versus 89% (AR).

However, patients in both groups with low Hb levels pre-treatment still had a worse overall survival irrespective of which treatment they received. This is most likely due the fact that many patients with head and neck cancer also have other health problems that cannot be treated by radiotherapy, the researchers say.

"In the past, a number of investigators have tried to improve the outcome for patients with low Hb levels by giving erythropoietin, which stimulates red blood cell production, and red cell blood transfusion before and during treatment, but without success. ARCON is the first treatment to be found to correct for low Hb and therefore to improve prognosis in these patients," says Dr. Janssens. "We know that a decrease in Hb levels is associated with a reduced sensitivity to radiotherapy, and that this can switch the tumour microenvironment into a more aggressive subtype with a higher risk of loco-regional failure and of the development of distant metastases."

The lack of success with transfusion of red blood cells or erythropoietin suggests underlying adaptive mechanisms. Accelerated radiotherapy to counteract tumour cell repopulation during radiotherapy, combined with carbogen and nicotinamide, administered immediately before irradiation to increase the oxygen level, ensures that adaptive mechanisms cannot erode the effect, and this is probably the key to success of the ARCON regime in patients with low HB levels at presentation, the researchers say.

"We believe that, at a time when healthcare systems are under increasing pressure to introduce expensive targeted treatments, the use of such a low cost, effective therapy should only be encouraged," Professor Kaanders will conclude.

Prof Vincenzo Valentini, radiation oncologist at the Policlinico Universitario A. Gemelli in Rome, Italy, and President of ESTRO, said: "We know that the degree of oxygenation of tumours in laryngeal cancer patients is directly related to the damage that can be caused to them by radiotherapy. This important study shows that, in patients with low haemoglobin levels, it is possible to reoxygenate the tumour by using the simple and cost-effective ARCON regime, and therefore increase the effectiveness of radiation treatment."

###

Abstract no: OC 217, 10.30 hrs, Friday 11 May, Auditorium

[1] When carbogen is inhaled, the increased level of carbon dioxide causes the brain to react to potential suffocation because it interprets the increase in blood carbon dioxide as a decrease in oxygen level, and the body compensates by reducing hypoxia. Nicotinamide also reduces hypoxia by increasing blood flow.

[2] This year the ESTRO conference is held in parallel with the World Congress of Brachytherapy, both taking place in Barcelona from May 9-13.

European Society for Radiotherapy and Oncology (ESTRO)


Related Radiotherapy Current Events and Radiotherapy News Articles


Vismodegib in basal cell carcinoma: Added benefit not proven
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG).

Vitamin A may help improve pancreatic cancer chemotherapy
Around 8,800 people in the UK are diagnosed with pancreatic cancer each year. It is known as the UK's deadliest cancer, with a survival rate of just 3 per cent.

Gene therapy against brain cancer
Only a few days ago, the press (especially in English-speaking countries) enthusiastically announced the publication of a study that described in great detail the genetics of breast cancer, a discovery that according to many marks a breakthrough in the battle against this cancer.

Radiotherapy halves deaths from prostate cancer 15 years after diagnosis
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis.

A better way to diagnose and manage neuroendocrine tumors
A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors (NETS), and could significantly impact treatment management.

Improvements to online health information can help reduce barriers to care for pancreatic cancer
The Internet has become a powerful and important resource for daily life. When patients receive a medical diagnosis, particularly a difficult one like pancreatic cancer, the web can be an essential information tool, helping to enable patients to have meaningful discussions with health care providers.

Failure to publish trial results exposes patients to risks without providing benefits
Although the publication of results of clinical trials carried out in the USA within 12 months of their completion has been mandatory since 2007, an astoundingly high number of Phase III radiotherapy trials did not do so, according to new research to be presented at the ESTRO 35 conference today (Saturday).

Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer.

Demand for radiotherapy will rise substantially over next 10 years
The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology.

UT Southwestern research shows 98 percent cure rate for prostate cancer using SBRT
A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center.
More Radiotherapy Current Events and Radiotherapy News Articles

Clinical Radiation Oncology, 4e

Clinical Radiation Oncology, 4e
by Leonard L. Gunderson MD MS FASTRO (Author), Joel E. Tepper MD (Author)


Perfect for radiation oncology physicians and residents needing a multidisciplinary, treatment-focused resource, this updated edition continues to provide the latest knowledge in this consistently growing field. Not only will you broaden your understanding of the basic biology of disease processes, you'll also access updated treatment algorithms, information on techniques, and state-of-the-art modalities. The consistent and concise format provides just the right amount of information, making Clinical Radiation Oncology a welcome resource for use by the entire radiation oncology team.Content is templated and divided into three sections -- Scientific Foundations of Radiation Oncology, Techniques and Modalities, and Disease Sites – for quick access to information. Disease Sites chapters...

Radiotherapy for Head and Neck Cancers: Indications and Techniques

Radiotherapy for Head and Neck Cancers: Indications and Techniques
by K. Kian Ang MD PhD (Author), Adam S. Garden MD (Author)


Long established as a staple reference for all radiation oncologists, Radiotherapy for Head and Neck Cancers: Indications and Techniques is now in its Fourth Edition. This completely updated edition presents the state-of-the-art protocols currently used at the MD Anderson Cancer Center and thoroughly explains the principles, nomenclature, and clinical use of intensity-modulated radiotherapy (IMRT). The first section discusses the practical aspects of external beam therapy, brachytherapy, and endocavitary beam therapy and offers guidelines on patient care before and during radiotherapy. The second section provides detailed coverage of site-specific indications and techniques.

Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy

Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy
by Rajni A Sethi (Editor), Igor J Barani (Editor), David A Larson (Editor), Mack Roach III (Editor)


This handbook concisely summarizes state-of-the-art information about stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT), including the history and development of these modalities, the biologic rationale for these technologies, typical practices, and reported results. Developed as a companion to Handbook of Evidence-Based Radiotherapy, Second Edition, edited by Eric Hansen and Mack Roach, III, it is organized by disease site and presents treatment techniques and recommended imaging; safety and quality assurance; toxicities and management; recommended follow-up; and supporting evidence. Inclusion of evidence-based guidelines is intended to help inform decisions regarding the appropriateness of SRS and SBRT and guide treatment and evaluation. Handbook of...

Proton and Charged Particle Radiotherapy

Proton and Charged Particle Radiotherapy
by Thomas F. DeLaney MD (Editor), Hanne M. Kooy MD (Editor)


This volume is the first comprehensive and practical clinical reference on proton and charged particle radiotherapy. The first half of the book explains the treatment delivery systems used, offers detailed guidance on treatment planning techniques, examines key clinical issues in proton radiotherapy, and reviews recent experience with heavier charged particle radiotherapy. The second half of the book offers "how-to" information on treatment of pediatric tumors, lymphomas, and tumors of the central nervous system, eye, skull base, cervical spine, bone and soft tissue, paranasal sinus, nasal cavity, nasopharynx, oropharynx, oral cavity, salivary glands, prostate, lung, gastrointestinal tract, female reproductive tract, and breast. More than 100 full-color illustrations complement the...

CT Anatomy for Radiotherapy

CT Anatomy for Radiotherapy
by Pete Bridge (Author)


Knowledge of CT anatomy is increasingly vital in daily radiotherapy practice, especially with more widespread use of cross-sectional image-guided radiotherapy (IGRT) techniques. Existing CT anatomy texts are predominantly written for the diagnostic practitioner and do not always address the radiotherapy issues while emphasising structures that are not common to radiotherapy practice. “CT Anatomy for Radiotherapy” is a new radiotherapy-specific text that is intended to prepare the reader for CT interpretation for both IGRT and treatment planning. It is suitable for undergraduate students, qualified therapy radiographers, dosimetrists and may be of interest to oncologists and registrars engaged in treatment planning. All essential structures relevant to radiotherapy are described...

The Physics of Radiotherapy X-Rays And Electrons

The Physics of Radiotherapy X-Rays And Electrons
by Peter Metcalfe (Author), Tomas Kron (Author), Peter Hoban (Author)


The Physics of Radiotherapy X-Rays and Electrons is an updated successor to The Physics of Radiotherapy X-Rays from Linear Accelerators published in 1997. This new volume includes a significant amount of new material, including new chapters on electrons in radiotherapy and IMRT, IGRT, and tomotherapy, which have become key developments in radiation therapy.

Also updated from the earlier edition are the physics beam modeling chapters, including Monte Carlo methods, adding those mysterious electrons, as well as discourse on radiobiological modeling including TCP, NTCP, and EUD and the impact of these concepts on plan analysis and inverse planning.

This book is intended as a standard reference text for postgraduate radiation oncology medical physics students. It will also be of...

Practical Radiotherapy Planning Fourth Edition

Practical Radiotherapy Planning Fourth Edition
by Ann Barrett (Author), Jane Dobbs (Author), Tom Roques (Author)


Planning is a critical stage of radiotherapy. Careful consideration of the complex variables involved and critical assessment of the techniques available are fundamental to good and effective practice.

First published in 1985, Practical Radiotherapy Planning has, over three editions, established itself as the popular choice for the trainee raditation oncologist and radiographer, providing the 'nuts and bolts' of planning in a practical and accessible manner.

This fourth edition encompasses a wealth of new material, reflecting the radical change in the practice of radiotherapy in recent years. The information contained within the introductory chapters has been expanded and brought up to date, and a new chapter on patient management has been added. CT stimulators, MLC...

  Alternate Fractionation in Radiotherapy: Paradigm Change (Medical Radiology)
by Mark Trombetta (Editor), Jean-Philippe Pignol (Editor), Paolo Montemaggi (Editor), Luther W Brady (Editor)


This book, written by leading international experts, describes alternate fractionation strategies in which technology-driven precise targeting and dosing allow for improved conformance and decreased volumes, with concordant lessening of toxicity, reduction in treatment time, and lower overall health care expense. The aim is to provide the advanced clinician with an up-to-date evidence-based reference that will assist in the delivery of enhanced patient care in daily practice. Traditional multi-week fractionation schedules were established at a time when the inclusion of relatively large amounts of normal tissue was unavoidable owing to the lack of accurate target localization during treatment. Such schedules are time and resource consuming, difficult for patients, and expensive....

Textbook of Radiotherapy

Textbook of Radiotherapy
by Gilbert Hungerford Fletcher (Editor)


Publications from the staff of the M. D. Anderson Hospital and Tumor Institute have earned a well deserved reputation for excellence. This volume is no exception. Written by present and past members of the staff of that institution, with Dr. Fletcher as editor, a high standard is maintained. Some sections have been written by experts from other institutions in fields where their special knowledge and experience would be of value. The general character of the book, however, is set by the practice and experience of the parent institution. The guiding principle of the presentation is to give a definite point of view and plan of treatment rather than a discussion of different principles and practices. This is not meant to imply that there are not other equally satisfactory approaches, but is...

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development)

Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development)
by Benjamin Bonavida (Editor)


This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.

© 2016 BrightSurf.com